The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...

They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...